tipifarnib
tipifarnib: sourced relationships with 1 company · 2 clinical trials tracked.
tipifarnib evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could tipifarnib → KURA affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Kura Oncology, Inc. (KURA) HNSCC; HRAS Mutations or Peripheral T Cell Lymphoma (PTCL) | Phase 2 |
Clinical Trial Registry Records (2)
Expanded Access to Tipifarnib
A Phase 1/2 Open-label, Biomarker-defined Cohort Trial to Evaluate the Safety, Determine the Recommended Combination Dosing, and Assess Early Antitumor Activity of Tipifarnib and Alpelisib for the Treatment of Adult Participants Who Have HRAS-overexpressing and/or PIK3CA-mutated and/or - Amplified Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Primary endpoint: Dose-limiting toxicity (DLT)
Frequently asked questions
Which companies have sourced relationships with tipifarnib?
tipifarnib has dated SEC/FDA relationship records for Kura Oncology, Inc..
How many clinical trials involve tipifarnib?
BioSniper tracks 2 clinical trials involving tipifarnib.